No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARWR240719C30000
- 0.03
- +0.02+200.00%
15min DelayClose Jul 19 15:58 ET
0.03High0.03Low
0.03Open0.01Pre Close9 Volume208 Open Interest30.00Strike Price27.00Turnover1070.18%IV6.11%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0648Delta0.1176Gamma943.33Leverage Ratio-14.2429Theta0.0000Rho61.17Eff Leverage0.0001Vega
Intraday
- 5D
- Daily
News
Analysts' Opinions Are Mixed on These Healthcare Stocks: CSL (OtherCMXHF) and Arrowhead Pharmaceuticals (ARWR)
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $54
BofA Securities analyst Jason Gerberry maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62
Piper Sandler analyst Edward Tenthoff maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and maintains the target price at $62.According to TipRanks data, the analyst has a success
TD Cowen Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Veeva Systems (VEEV) and Arrowhead Pharmaceuticals (ARWR)